-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Latest From Biotech Now
2011 BIO International Convention: The evolution of one-on-one partnering
From the beginning, networking has been a central focus at BIO’s events. Our members attend our conferences primarily to seek out business opportunities and to meet other biotech executives. When company presentations were introduced at the 1998 BIO International Convention, delegates registered for the conference by mail and fax and presentations were the key means for companies to tell their stories at BIO’s early events. With BIO members asking for introductions to pharmaceutical companies, BIO Read More >
Counterfeiting: White House IP Czar Victoria Espinel on working with corporations
White house IP Czar Victoria Espinel spoke at BIO’s 2011 International Convention in a session titled Counterfeiting: How corporations and government can work together. She told the audience that when entering her new assignment she was surprised to find out that counterfeiting was a large problem in the United States and not just abroad. The Administration has increased enforcement in counterfeit medicines as seizures of health related counterfeits have gone up 97% from last year. Read More >
Innovative China: Policies for the Future
As the second largest and fastest growing market for biotechnology products, China needs no introduction. The opportunity to heal, fuel, and feed 1.3 billion global citizens stands in clear contrast with the regulatory, financial, and political frameworks that present challenges to the life science industry’s external access to the evolving Chinese market. On Tuesday at the 2011 BIO International Convention, a panel discussion titled “Innovative China: Policies for the Future” addressed the future of the Read More >
Current Challenges in Payment Reform
By Alyson Pusey, BIO. The Affordable Care Act created several demonstration projects to test innovative care delivery systems that increase quality of care while decreasing costs. Speaking as a panelist was Jonathan Blum, Deputy Administrator and Director of the Center for Medicare at CMS, who discussed how the agency is thinking about payment reform. Evidenced by the recent proposed rule on accountable care organizations (ACOs), the agency is looking to providers and the health care Read More >
Biotechnology Innovation: Impact of Health Reform and Deficit Control
By Alyson Pusey, BIO. With many governors around the country facing budget shortfalls, “the action is all in the states” in terms of health care cuts and cost-savings solutions, according to panelists participating. The current fiscal environment has forced cash-strapped states to look at their Medicaid programs for ways to rein in costs, and according to panelists, state lawmakers will continue to do so for the foreseeable future. For example, as a result of the Read More >
